Drugs that contain Olaparib
1. Lynparza patents expiration
LYNPARZA's oppositions filed in EPO
LYNPARZA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7151102 | ASTRAZENECA | Phthalazinone derivatives |
Apr, 2022
(1 year, 11 months ago) | |
| US7449464 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(5 months from now) | |
| US7981889 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(5 months from now) | |
| US8247416 | ASTRAZENECA | Phthalazinone derivative |
Sep, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8912187 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(a month ago) | |
| US9566276 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(a month ago) | |
| US9169235 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(a month ago) | |
| US8071579 | ASTRAZENECA | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8143241 | ASTRAZENECA | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(3 years from now) | |
| US11633396 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
Oct, 2029
(5 years from now) | |
| US8475842 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Dec, 2029
(5 years from now) | |
| US8859562 | ASTRAZENECA | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-180) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-181) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-226) | Dec 19, 2025 |
| Orphan Drug Exclusivity(ODE-283) | Dec 27, 2026 |
| Orphan Drug Exclusivity(ODE-306) | May 08, 2027 |
| New Indication(I-914) | May 31, 2026 |
| New Indication(I-885) | Mar 11, 2025 |
| New Product(NP) | Aug 17, 2020 |
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| New Indication(I-818) | Dec 27, 2022 |
| New Indication(I-762) | Jan 12, 2021 |
| New Indication(I-831) | May 08, 2023 |
| New Indication(I-832) | May 19, 2023 |
| New Indication(I-776) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
NCE-1 date: 19 December, 2018
Market Authorisation Date: 17 August, 2017
Treatment: Treatment of brca mutated ovarian cancer using parp inhibitor; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not pr...
Dosage: TABLET;ORAL; CAPSULE;ORAL
How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage
LYNPARZA family patents
